Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 120
- Registration Number
- NCT01119677
- Locations
- 🇺🇸
Research Site, Saint Paul, Minnesota, United States
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 38
- Registration Number
- NCT01085318
- Locations
- 🇺🇸
EMD Serono, Inc., Rockland, Massachusetts, United States
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
- Conditions
- Multiple Sclerosis, Relapsing Remitting
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 254
- Registration Number
- NCT01080027
- Locations
- 🇬🇷
Neurology Clinic, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, Greece
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 300
- Registration Number
- NCT01075880
- Locations
- 🇨🇿
Neurologicka klinika FNBB, Brno, Czech Republic
🇨🇿Neurologicka klinika, Fakultní nemocnice U Sv. Anny, Brno, Czech Republic
🇨🇿Neurologicka klinika, Fakultní nemocnice, Olomouc, Czech Republic
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 42
- Registration Number
- NCT01075763
- Locations
- 🇮🇹
U.VA. Neurologia - Azienda Ospedaliera Garibaldi Nesina, Catania, CT, Italy
Treatment Interruption of Natalizumab
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 175
- Registration Number
- NCT01071083
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 84
- Registration Number
- NCT01058005
- Locations
- 🇸🇪
Research Site, Molndal, Sweden
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
- Conditions
- Multiple Sclerosis
- Interventions
- Device: Single-use autoinjector
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2009-06-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 74
- Registration Number
- NCT00915577
A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 96
- Registration Number
- NCT00913250
Immunogenicity and Safety Study of Serum-Free Avonex
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 155
- Registration Number
- NCT00912860
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.